Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Exelixis Inc
(NQ:
EXEL
)
21.37
+0.32 (+1.52%)
Streaming Delayed Price
Updated: 10:29 AM EST, Nov 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
223,045
Open
21.02
Bid (Size)
21.37 (8)
Ask (Size)
21.38 (5)
Prev. Close
21.05
Today's Range
20.95 - 21.38
52wk Range
15.32 - 22.80
Shares Outstanding
315,048,788
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NASDAQ:EXEL, a growth stock which is not overvalued.
Today 8:40 EST
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.
Via
Chartmill
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
November 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Performance
YTD
+31.10%
+31.10%
1 Month
+5.58%
+5.58%
3 Month
-4.60%
-4.60%
6 Month
+11.88%
+11.88%
1 Year
+27.28%
+27.28%
More News
Read More
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
November 10, 2023
From
Exelixis, Inc.
Via
Business Wire
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Via
InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
November 06, 2023
Via
Chartmill
Where Exelixis Stands With Analysts
November 02, 2023
Via
Benzinga
Earnings Outlook For Exelixis
October 31, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
October 18, 2023
Via
The Motley Fool
3 Biotech Stocks With the Strongest Clinical Pipelines
November 08, 2023
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Via
InvestorPlace
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
November 02, 2023
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 01, 2023
From
Exelixis, Inc.
Via
Business Wire
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
October 28, 2023
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
14 Analysts Have This to Say About Exelixis
October 11, 2023
Via
Benzinga
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
Via
FinancialNewsMedia
Why Exelixis Stock Is Trading Lower Today
October 23, 2023
Via
Benzinga
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
October 22, 2023
From
Exelixis, Inc.
Via
Business Wire
3 Under-the-Radar Biotech Stocks to Buy in 2023
October 19, 2023
Via
The Motley Fool
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
October 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
October 13, 2023
Via
Chartmill
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
October 02, 2023
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
September 29, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 26, 2023
September 26, 2023
Via
Benzinga
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
September 20, 2023
Via
InvestorPlace
Week In Review: Hasten Signs $325 Million Deal For China Rights To PCSK9 Cholesterol Therapy
September 16, 2023
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.